Project Grant R43CA228686

This Project Grant award from the National Cancer Institute (NCI), under the CFDA program 93.394 Cancer Detection and Diagnosis Research, provides $927,997.00 to Lagrange Scientific LLC to develop a prognostic assay for metastatic clear cell renal cell carcinoma (CCRCC). The goal is to identify a panel of metabolite biomarkers that can accurately predict early progression to metastasis in CCRCC patients, enabling earlier initiation of systemic therapy. The award will support further...

This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is focused on developing a novel, non-invasive urine test for the early detection of kidney cancer. The $305,000 award to Cicadea Biotech LLC, a woman-owned small business, aims to demonstrate the specificity and accuracy of a biomarker for detecting renal tumors in early-stage kidney cancer patients without symptoms, as well as its...

The National Cancer Institute (NCI) awarded a $215,985 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University to study exosome signatures as early biomarkers for predicting response to immune checkpoint inhibitor therapy in metastatic renal cell carcinoma (RCC) patients. The key objectives are to: 1) Define an exosome signature of response by analyzing exosomal transcripts in blood and urine at baseline, 3 weeks, and 6 weeks of treatment...

This $172,193 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the Dana-Farber Cancer Institute (DFCI) to improve diagnosis and treatment of translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer. The key objectives are to: 1) develop optimization methods to identify differential activity of transcription factors that drive TRCC progression, 2) build predictive metabolic models to discover...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research by the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, spanning 2 years from February 2025 to January 2027, will fund genetic and pharmacological studies to assess the sensitivity of TRCC cells to CDK4/6...

The Cleveland Clinic Foundation will investigate the importance of the gut microbial endocrine organ in kidney cancer development and therapeutic response under a $585,798 project grant from the Department of the Army Medical Command. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield wounds...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $348,657 to the Hennepin Healthcare Research Institute (HHRI) to develop a clinical decision support tool to improve understanding of the survival benefit of kidney transplantation for end-stage kidney disease (ESKD) patients with a history of cancer. The key objectives are to: 1)...

The National Cancer Institute awarded a $546,349 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The University of Texas Southwestern Medical Center to conduct research on the role of the von Hippel-Lindau (VHL) tumor suppressor in regulating gene expression through N6-methyladenosine (m6A) modification of mRNA in clear cell renal cell carcinoma (ccRCC). The research aims to determine the molecular mechanism by which VHL regulates m6A modification, and to examine the...

This federal Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the associations of dietary patterns and physical activity with renal cell carcinoma (RCC) survival. The $189,163 award to Brigham & Women's Hospital will fund a comprehensive study using data from three large prospective cohorts to evaluate the impact of pre- and post-diagnostic adherence to various dietary patterns and...

This Project Grant award of $1,198,458 from the Department of the Army Medical Command's Military Medical Research and Development program will fund research evaluating human leukocyte antigen (HLA) class II evolutionary divergence as an immunotherapy-specific biomarker for kidney cancer. The Sloan-Kettering Institute For Cancer Research will conduct the research from September 2021 through September 2025. A subaward of $TBD to the Icahn School of Medicine at Mount Sinai supports related work on...